CDDC to discuss partial reimb of anticancer drug combos

to be implemented in June

35 of 54 cases to be announced... treatments exceeding approval limits excluded

May be announced with the reimbursement standards for anticancer drugs... list to be continuously updated

The Health Insurance Review and Assessment Service announced today (14th) that it held a Cancer Disease Review Committee meeting and discussed the list of drugs eligible for partial reimbursement as anticancer drug combination therapies, as it had recently announced.

 

The reimbursement standard for anticancer drugs will be revised starting next month based on the list made today.

 

The details discussed at the meeting are expected to be disclosed when the reimbursement standard for anticancer drugs is announced.

 

The Health Insurance Review and Assessment Service (President Jung-Gu Kang) announced that it had deliberated on the “Reimbursement Standards for Drugs Used for Cancer Patients” at the 4th Cancer Disease Deliberation Committee meeting in 2025.

 

The details discussed on that day are follow-up measures to the revision of the general principles regarding “the scope and cost burden of drugs prescribed and administered to cancer patients among severely ill patients as drugs determined and announced by the Health Insurance Review and Assessment Service in accordance with Article 5, Paragraph 4 of the Rules on National Health Insurance Medical Care Benefits” among the details on the application criteria and methods for medical care benefits.

 

At the meeting, the committee discussed the list of combination therapies eligible for reimbursement coverage, taking into account the indication and opinions from academic societies, with the aim of reducing confusion in clinical practice and enhancing predictability when applying the detailed guidelines to existing anticancer therapies and combination therapies with other anticancer drugs.

 

The revised list will take effect on June 1.

 

A total of 54 combination therapies were discussed, and 35 will be included in the revised guidelines.

 

Therapies exceeding the approved indication were excluded.

 

This decision was made as a minimum safety measure against the inappropriate use of combination therapies, such as those exceeding approved indications.

 

The authorities explained that in the future, when academic societies submit requests for combination therapies related to this matter, the Cancer Disease Review Committee will review them and update the list of eligible therapies.